Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study Journal Article
| Authors: | Landgren, O.; Weisel, K.; Rosinol, L.; Touzeau, C.; Turgut, M.; Hajek, R.; Mollee, P.; Kim, J. S.; Shu, N.; Hu, X.; Li, C.; Usmani, S. Z. |
| Article Title: | Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study |
| Abstract: | CANDOR compared the safety/efficacy of carfilzomib with dexamethasone and daratumumab (KdD) to carfilzomib with dexamethasone (Kd) in adults with relapsed/refractory multiple myeloma (RRMM). This CANDOR subgroup analysis evaluated outcomes based on cytogenetic risk. Overall response rates (KdD vs. Kd) were 81% versus 56% in high-risk and 87% versus 79% in standard-risk groups. Median progression-free survival was 11.2 versus 7.4 months in high-risk (hazard ratio, 0.56 [95% CI, 0.34, 0.93]) and not reached versus 16.6 months in standard-risk groups (0.56 [95% CI, 0.39, 0.80]). These data support the efficacy of KdD in RRMM treatment, including in patients with high-risk cytogenetics. © 2022 British Society for Haematology and John Wiley & Sons Ltd. |
| Keywords: | proteasome inhibitor; cytogenetics; carfilzomib; relapsed or refractory multiple myeloma |
| Journal Title: | British Journal of Haematology |
| Volume: | 198 |
| Issue: | 6 |
| ISSN: | 0007-1048 |
| Publisher: | John Wiley & Sons |
| Date Published: | 2022-09-01 |
| Start Page: | 988 |
| End Page: | 993 |
| Language: | English |
| DOI: | 10.1111/bjh.18233 |
| PUBMED: | 35608261 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 3 October 2022 -- Source: Scopus |
